<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/60063E07-6052-43FB-A74D-4DFC63798803"><gtr:id>60063E07-6052-43FB-A74D-4DFC63798803</gtr:id><gtr:firstName>Irene</gtr:firstName><gtr:surname>Roberts</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12009%2F14"><gtr:id>2B0CFBA5-D982-4980-887C-8BE952E35065</gtr:id><gtr:title>The impact of trisomy 21 on early human haematopoiesis</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12009/14</gtr:grantReference><gtr:abstractText>Accumulating evidence shows that many childhood leukaemias start to develop before birth. We believe that one of the most important reasons for this is the unique properties of the blood cells, including stem cells, which are responsible for blood production during fetal life. In particular our research focuses fetal haemopoiesis in Down syndrome because we know that children with Down syndrome, have a markedly increased chance of developing leukaemia in early childhood. We know that this increase in leukaemia is likely to be due to the presence of an extra copy of chromosome 21 (three copies instead of 2 copies) in the blood cells of children with Down syndrome. This is known as Trisomy 21. So far we have discovered that trisomy 21 causes major alterations in the behaviour of fetal blood cells causing them to produce an imbalance in blood cell production.and a high frequency of mutations in the GATA1 gene. We are now investigating the mechanisms by which trisomy 21 exerts these effects. This work has already had implications for management of newborn babies with Down syndrome and we hope will provide important insight into the early stages of leukaemia development in children with and without Down syndrome.</gtr:abstractText><gtr:technicalSummary>Children with Down syndrome (trisomy 21) are uniquely highly susceptible to both acute myeloid leukaemia (ML) and acute lymphoblastic leukaemia (ALL) in early childhood. ML, and possibly ALL, originate in fetal cells and we have previously shown that trisomy 21 itself perturbs fetal haemopoietic stem and progenitor cell (HSPC) biology. We now want to identify the molecular mechanisms which explain how the presence of 3 
copies of chromosome 21 produces specific defects in fetal HSPC and how this contributes to leukaemogenesis in children with Down syndrome.
Specific objectives:
1. To determine the impact of trisomy 21 on:
a) numbers and characteristics of fetal liver HSC: specifically, whether there is a true increase in megakaryocyte-biased HSC and the molecular basis for differences in the composition and function of trisomic versus normal disomic fetal liver HSC;
b) the molecular and functional characteristics of fetal liver megakaryocyte and megakaryocyte-erythroid progenitors; 
c) fetal liver and bone marrow B progenitor development, including the molecular basis for the PreProB to ProB progenitor transition block and susceptibility to leukaemic transformation.
2. To determine whether the effects of trisomy 21 are unique to fetal liver by investigating the numbers and characteristics of HSC, progenitors and mature haemopoietic cells in trisomy 21 fetal bone marrow compared to normal (disomic) bone marrow.
3. To determine the clinical and biological significance of acquired GATA1 mutations on trisomy 21 fetal and neonatal haemopoietic cells in a prospective cohort study of children with Down syndrome from birth to age 5 years (collaboration with Paresh Vyas' lab) by:
a) serial analysis of clinical and haematological features in the presence and absence of acquired GATA1 mutations, mutant GATA1 clone size and acquisition of co-operating molecular events in leukaemic transformation;
b) using statistical modelling to identify prognostic clinical, haematological and molecular parameters which predict transformation to leukaemia;
Experimental approach and methodology:
We will continue to work on primary human fetal cells as no mouse models or ES/iPS models fully recapitulate the human disease. Consistent differences in global gene expression patterns in highly purified normal and trisomy 21 haemopoietic stem and progenitor populations will be sought, focusing on differences where expression of chromosome 21 genes is likely to be implicated. Overexpression, knockdown and gene editing of primary cells will be used to test the functional significance of these changes. The role of the trisomy 21 microenvironment will be investigated directly (through gene expression of trisomic and disomic fetal liver stromal cells) and indirectly in vitro and in vivo. 
Wider implications of the research and translation into clinical benefit for patients: The ultimate aim is to determine which children with Down syndrome will develop ML-DS and to effectively intervene in the transformation process to actively prevent the development of leukaemia using minimally toxic, targeted therapy. Increased understanding of how trisomy 21 transforms haemopoietic cells in children with Down syndrome may also provide insight into acute leukaemia in children without Down syndrome, where trisomy 21 is the commonest acquired chromosomal anomaly, and into the impact of aneuploidy on cell growth and differentiation in cancer in general.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>384000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Statistics</gtr:department><gtr:description>Statistics and mathematical modelling</gtr:description><gtr:id>A8CA0BFB-CF13-4FCD-8344-BC5A518107E8</gtr:id><gtr:impact>Joint publications.</gtr:impact><gtr:outcomeId>56793a3872b6a3.11359186-1</gtr:outcomeId><gtr:partnerContribution>Intellectual discussions. Statistical analysis. Mathematical modelling.</gtr:partnerContribution><gtr:piContribution>Generated data. Intellectual discussions.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Intellectual, methodological and analytical trisomy 21 collaboration</gtr:description><gtr:id>73D43AD5-ABD5-464A-B72E-3F62FACCA682</gtr:id><gtr:impact>Joint grants and publications. Joint supervision of doctoral and post-doctoral students</gtr:impact><gtr:outcomeId>56793905174cb1.11514262-1</gtr:outcomeId><gtr:partnerContribution>Longstanding collaboration based on shared lab space and lab meetings, intellectual discussions, sharing techniques and data. Particular expertise in lentivirus construction and infection protocols and epigenetics</gtr:partnerContribution><gtr:piContribution>Longstanding collaboration based on shared lab space and lab meetings, intellectual discussions, sharing techniques and data. Our group has particular expertise in fetal haematopoiesis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Ormond Street Hospital (GOSH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Childhood leukaemia and preleukaemia</gtr:description><gtr:id>3E6FE595-1ABF-4801-8795-6AFACF094F19</gtr:id><gtr:impact>Joint grant application.</gtr:impact><gtr:outcomeId>567979f030a497.82816044-1</gtr:outcomeId><gtr:partnerContribution>Phenotypic characterisation and molecular analysis.</gtr:partnerContribution><gtr:piContribution>Haematopoietic stem and progenitor cell analysis functional and molecular analysis.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Effects of trisomy 21 on early development</gtr:description><gtr:id>08FD3E9D-698C-4E3E-A45C-68BF89502CB5</gtr:id><gtr:impact>Joint publications</gtr:impact><gtr:outcomeId>56793bccd21b72.07590265-1</gtr:outcomeId><gtr:partnerContribution>Study design, identification of cases, contribution to publications</gtr:partnerContribution><gtr:piContribution>Study design, sample processing, generation and analysis of data, writing papers.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Neonatal Down Syndrome Study</gtr:description><gtr:id>6BC49A19-6860-41B2-AE68-6C27562A5655</gtr:id><gtr:impact>Joint publications.</gtr:impact><gtr:outcomeId>56797b0696b803.29405229-1</gtr:outcomeId><gtr:partnerContribution>Study design. Data analysis. Writing papers.</gtr:partnerContribution><gtr:piContribution>Study design. Morphological and genetic analysis of haematological cells in neonates and children. Data analysis and writing of papers.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>Fetal haematopoietic stem and progenitor cells (especially EMPs) and leukaemic transformation- JMML and EZH2 models</gtr:description><gtr:id>4B74E165-F1A6-41A8-A7C5-2546AE23DBC5</gtr:id><gtr:impact>Work on the project began in September 2016</gtr:impact><gtr:outcomeId>58c3ea397be339.11550496-1</gtr:outcomeId><gtr:partnerContribution>The partner lab provides extensive expertise in mouse modelling of these disorders which my group does not have.</gtr:partnerContribution><gtr:piContribution>We are exploring the hypothesis that common mechanisms underlying the leukaemogenic impact of trisomy 21 on fetal haematopoiesis and in utero initiation of leukaemia in Juvenile Myelomonocytic Leukaemia which shares a very similar natural history and myeloproliferative phenotype to trisomy 21-associated myeloid leukaemia in early life. We have successfully applied for a joint clinical research fellowship to investigate this hypothesis. My group provides the expertise in human normal and trisomy 21 haematopoiesis at the functional and molecular level.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Human Genome Research Institute (NHGRI)</gtr:department><gtr:description>Megakaryocyte biology</gtr:description><gtr:id>5B544F80-1C65-4013-BF2F-6EB0B1E16AA1</gtr:id><gtr:impact>Joint publication submitted.</gtr:impact><gtr:outcomeId>5679508f88ed73.11978135-1</gtr:outcomeId><gtr:partnerContribution>Megakaryocyte functional and molecular studies</gtr:partnerContribution><gtr:piContribution>Molecular and functional analysis of human haematopoietic cells</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>Human fetal haematopoietic stem cells</gtr:description><gtr:id>5E715C30-F57C-4E02-960E-FFF4F90B9BD5</gtr:id><gtr:impact>New project initiated January 2017 after funding awarded October 2016</gtr:impact><gtr:outcomeId>58c3e72aca28b6.05477800-1</gtr:outcomeId><gtr:partnerContribution>Isolation of candidate stem cell populations and their immunophenotypic and functional validation</gtr:partnerContribution><gtr:piContribution>Collaborative project to identify and characterise sub-populations of human fetal haematopoietic stem cells as a platform for elucidating the mechanism of the differences mediated by trisomy 21</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cytogenetic analysis</gtr:description><gtr:id>2FA3D871-C98C-4BD4-96AD-753B7B5BAB2B</gtr:id><gtr:impact>Abstract submitted. Paper in preparation.</gtr:impact><gtr:outcomeId>56797c3e2a6096.55252474-1</gtr:outcomeId><gtr:partnerContribution>Results of karyotypic analysis of neonates with Down syndrome.</gtr:partnerContribution><gtr:piContribution>Study design. Morphological and genetic analysis of haemopoietic cells in neonates and children with Down syndrome</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Down syndrome myeloid leukaemias</gtr:description><gtr:id>33E31FA2-683A-438D-87A4-07E88E22AC24</gtr:id><gtr:impact>Renewal of Programme 2013-2018
Publications</gtr:impact><gtr:outcomeId>5460bc461ffce0.42809895-1</gtr:outcomeId><gtr:partnerContribution>Joint project</gtr:partnerContribution><gtr:piContribution>Joint Programme Grant (Leukaemia and Lymphoma Research</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>Fetal pathogenesis of leukaemia- trisomy 21. MLL and infant leukaemia</gtr:description><gtr:id>7CAD5809-6796-46AC-91A7-39B1FE437143</gtr:id><gtr:impact>Publication: doi: 10.1016/j.celrep.2016.12.054</gtr:impact><gtr:outcomeId>58c3ec3ed73496.40042097-1</gtr:outcomeId><gtr:partnerContribution>Expertise in epigenetic techniques and analysis.</gtr:partnerContribution><gtr:piContribution>Our group contributes expertise in human normal and trisomy 21 fetal B lymphopoiesis- isolation, immunophenotypc/functional and gene expression.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Student presentations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E362B009-337A-403A-B20D-0BA4727C8C50</gtr:id><gtr:impact>Participated in student presentations both at Imperial College London (up to October 2013) and the Weatherall Institute of Molecular Medicine (WIMM), University of Oxford stimulate discussion and led to later discussions with individual students keen to explore opportunities for scientific research.

Regular approaches from clinical and non-clinical students keen to explore careers in paediatric haematology research.</gtr:impact><gtr:outcomeId>5679c827698761.74420752</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Down Syndrome Association</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0DAC2C84-03E2-4CF1-968C-862F7895DACD</gtr:id><gtr:impact>Participated in 2 workshops to describe and explain the haematological problems in children with Down syndrome and to exchange information with both researchers and the Down Syndrome Association, the principal UK patient and family-led support group. Participation led to sharing of information between research groups in Down syndrome as well as establishing direct communication with the Down Syndrome Association to share clinical and research information in a bidirectional fashion.

Follow up visit to the Down Syndrome Association in July 2015 to share information about proposed guidelines for neonates and children with Down syndrome and establish a mechanism for patient/family support into guideline development.</gtr:impact><gtr:outcomeId>5679c517c8bf15.31556546</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012,2013,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Guidelines for Down syndrome Transient Leukaemia and Myeloid Leukaemia</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>54FD2550-C2AA-4114-8408-98F8026C69D5</gtr:id><gtr:impact>These guidelines are the first to provide guidance about the appropriate haematological investigations and management of newborn infants with Down syndrome (~750-800 per year), the appropriate follow up of the 30% of neonates who have acquired, preleukaemic GATA1 gene mutations and the management of the 5-12% of these children who subsequently develop acute myeloid leukaemia.

First national guidelines for haematological investigation and management of newborns with Down syndrome- strengthened by endorsement by neonatologists, haematologists and paediatric haematologists.</gtr:impact><gtr:outcomeId>5679c02aca7f50.76050094</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>James Lind Alliance</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BCA65B24-397F-4F8B-916C-7397B47E70CB</gtr:id><gtr:impact>The all day meeting involved a separate session at the end for the Patient Representatives to meet with the facilitators to provide their feedback which was extremely positive. A questionnaire will be devised by the Steering Group to obtain the views of patients throughout the UK as well as other stakeholders about the priorities for research. The Steering Group, including the Patient Representatives, will meet monthly (face to face or by teleconference) over the next 12 months to devise the questionnaire and analyse the results.

The Steering Group, including the Patient Representatives, will meet monthly (face to face or by teleconference) over the next 12 months to devise the questionnaire and analyse the results. The impact beyond the first meeting will be assessed at future meetings.</gtr:impact><gtr:outcomeId>5679c61fd15081.59871747</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Down syndrome neonatal study- website blog/article</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>059B63C3-236E-4E22-BAB7-5235857AA041</gtr:id><gtr:impact>Research nurse on the trisomy 21 project (neonatal aspects) participated in a Bloodwise nurses forum and was invited to prepare a blog for the Bloodwise website which was posted in February 2017</gtr:impact><gtr:outcomeId>58c412e0758136.34102251</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>467860</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Kay Kendall Leukaemia Fund Equipment Grant</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:fundingRef>KKL1057</gtr:fundingRef><gtr:id>ED4AC16B-3B44-479B-B4EB-18808A5349E8</gtr:id><gtr:outcomeId>56dff8f78c80d3.74452437</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>221922</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Fellowship</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>E5F91145-9F7F-49FB-AF13-0B8843E0FB68</gtr:id><gtr:outcomeId>5461ed452f9782.05210774</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>650000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Rare Disease-Translational Research Collaboration</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>5EEEEEE1-D5CD-446D-AD55-E12295607861</gtr:id><gtr:outcomeId>5461eb5c6341b8.54530547</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300795</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Training Fellowship, University of Oxford</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>183221</gtr:fundingRef><gtr:id>BE8BDBCA-8AAB-4AE1-BA83-12BD195768DC</gtr:id><gtr:outcomeId>56798a827f3716.95922483</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>47059</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Oxford University Hospitals/NIHR Research Capability Fund</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>A2FEF8A2-2D21-4CBD-935F-62A41ECF6A07</gtr:id><gtr:outcomeId>56798929185aa0.73788745</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European Hematology Association Research Roadmap (3 sections: 1.6 Developmental; 4.5 Congenital bone marrow failure; 5.3 Thrombocytopenia- fetal/neonatal alloimmune)</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>FCB664E6-AC15-48C7-9490-48122AADF699</gtr:id><gtr:outcomeId>567a6eb378d784.81186454</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/26819058</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Guidelines for Down syndrome Transient Leukaemia and Myeloid Leukaemia</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>The investigation and management of Transient Leukaemia of Down Syndome (TL-DS)</gtr:guidelineTitle><gtr:id>C9455D75-DCED-48CC-B4A3-581B497C4F71</gtr:id><gtr:impact>The aim is to achieve equity of care across centres in the UK which we know is currently not available. The guidelines have been adopted by all relevant professional bodies including the Royal College of Paediatrics and Child Health, the British Society of Haematology (British Committee for Standards in Haematology) and the NCRI Childhood Leukaemia Clinical Network (CLCN).</gtr:impact><gtr:outcomeId>5679cce1325a13.80137787</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oxford Genomic Medicine MDT</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>EBD2D2CC-8A26-4978-BA1C-3C8BA4D79B7B</gtr:id><gtr:impact>I have been a member of the Oxford University Hospitals Genomic Medicine MDT since it was established early in 2014 to provide guidance and oversight of referrals of samples from families with suspected genetic disease for whole genome sequencing. This committee is one of the first in the UK to be established and has also developed guidelines for the complex issues surrounding interpretation and communication of the results. The committee has regular visitors from other hospitals and from abroad to observe the processes used and under development in this committee.</gtr:impact><gtr:outcomeId>567a69754b3900.46358460</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Athena Swan and Women in Science</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>39C00A08-DD2B-45A2-B9CB-5D2EBC53A97B</gtr:id><gtr:impact>As a member, and now Chair, of the University of Oxford Department of Paediatrics Athena Swan Committee, we successfully achieved an Athena Swan Silver Award at the first attempt this year. This reflects real improvements in raising the actual numbers, as well as awareness, of women at all levels in our academic department. Opportunities for women have also been increased and changes made in the running of the department which allow women to participate fully. My role has been facilitated by also being a member of the Women in Science Committee of the Weatherall Institute of Molecular Medicine.</gtr:impact><gtr:outcomeId>567a67aa522259.51249739</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Research Committee, European Hematology Association</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>F8B0AB5B-F7A8-4125-93CB-326FD4E2CAC9</gtr:id><gtr:outcomeId>567a6f1bc45232.94866164</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Theme Lead for Non-Malignant Haematology, NIHR Rare Diseases-Translational Research Collaboration</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A2AC9D4D-CF8C-4B01-9A25-4D5B84B30412</gtr:id><gtr:impact>Since appointed as Theme Lead (in December 2013) I have built collaborative networks across the UK to facilitate translational research in rare anaemias and paediatric myelodysplastic syndromes and helped to support new networks in other rare non-malignant haematological disorders. This work began to deliver in 2014 and continues to build. The outputs include several clinical research fellowships, development of new management guidelines, 2 new studies which are collecting biological and clinical phenotypic data to match with genomic data (newly developed targeted next generation sequencing) and, via NIHR BioResource and the 100,000 Genomes Project, whole genome sequencing. One of these projects has also started a priority setting initiative in rare anaemias with the James Lind Alliance.</gtr:impact><gtr:outcomeId>56e0a2eb851d16.13666258</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://rd.trc.nihr.ac.uk</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>This is the first ever prospective observational study of haematological parameters and analysis of acquired preleukaemic mutations in the GATA1 gene from birth to age 5 years, the time period which spans the unique susceptibility of young children with Down syndrome to mutant GATA1-associated acute myeloid leukaemia (known as Myeloid Leukaemia of Down Syndrome, ML-DS). The study aimed to recruit 400 neonates. In our analysis of the first 200 neonates we reported a very high frequency of acquired GATA1 mutations (30%) which was reported in December 2013, more than half of which are clinically silent. This has major implications for screening and monitoring of newborns and children with Down syndrome and has led to ongoing dialogue with the Down Syndrome Association and the creation of a joint initiative between the British Society for Haematology, Royal College of Paediatrics and Child Health and British Society of Perinatal Medicine to develop guidelines to manage preleukaemia and ML-DS in Down syndrome. Update March 2017: Final ratification of these guidelines was confirmed on 10.3.17 and an implementation plan has been prepared with a goal of roll out in June 2017.</gtr:description><gtr:id>132A62B9-7F1F-457B-9012-2173F4C03ABC</gtr:id><gtr:impact>The full impact of the study will not be clear until it is complete and the guidelines have been trialled and audited. Planned for June 2017.</gtr:impact><gtr:outcomeId>56e0a91aa6e381.37403444</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Haematological abnormalities at birth in neonates with Down syndrome</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Single cell transcriptomic data published in our paper on MEP heterogeneity (Psaila et al, Gen Biol, 2016, PMID 27142433) and available online has been used by another group to develop an information theoretical framework to infer candidate gene (co-)regulatory networks and distill mechanistic hypotheses generalisable to other model systems (Babtie A, et al, bioRxiv- in press).</gtr:description><gtr:id>924770DA-92DC-497C-9CC5-3B5291E6886B</gtr:id><gtr:impact>Used by Michael Stumpf's group (Systems Biology, Imperial College London) to develop an information theoretical framework to infer candidate gene (co-)regulatory networks and distill mechanistic hypotheses generalisable to other model systems (Babtie A, et al, bioRxiv- in press, no PMID yet but pre-publication m/s shared with us).</gtr:impact><gtr:outcomeId>58c41cfe3d1421.93769106</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Megakaryocyte erythroid progenitor (MEP) single cell transcriptomic data for network inference</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0EB18004-25FE-451B-9D9D-07EF562BC826</gtr:id><gtr:title>Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4251f05b7fd9853ca6fa719ee5ba2ee0"><gtr:id>4251f05b7fd9853ca6fa719ee5ba2ee0</gtr:id><gtr:otherNames>Iskander D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>567a82c08ff404.57276150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D96FF54-F61A-42D8-94D8-111E50D850EF</gtr:id><gtr:title>Haematopoietic development and leukaemia in Down syndrome.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b244db03523acfcca3e96a5f37df371"><gtr:id>8b244db03523acfcca3e96a5f37df371</gtr:id><gtr:otherNames>Roberts I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5461f4426a7eb3.44007614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20A6745E-2BA5-4FAB-86F9-D372ABDD45E0</gtr:id><gtr:title>GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56314d300d185f04fed4e5d838e1f1b"><gtr:id>d56314d300d185f04fed4e5d838e1f1b</gtr:id><gtr:otherNames>Maroz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>5461ef9e9522a4.66340747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE9F3F74-D436-4BB5-923D-61727A2350A3</gtr:id><gtr:title>Nuclease-stimulated homologous recombination at the human ?-globin gene.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6dee36ffaabf74985f111eeb3d2b44e4"><gtr:id>6dee36ffaabf74985f111eeb3d2b44e4</gtr:id><gtr:otherNames>Vannocci T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn><gtr:outcomeId>5461f2bc069dd2.97814876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D576B911-951A-466B-9AB4-6A2C46801C36</gtr:id><gtr:title>Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.</gtr:title><gtr:parentPublicationTitle>Current hematologic malignancy reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ffacc5d7a7ea76b73eb0cef1a95f511"><gtr:id>6ffacc5d7a7ea76b73eb0cef1a95f511</gtr:id><gtr:otherNames>Bhatnagar N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1558-8211</gtr:issn><gtr:outcomeId>58c3dee58f6813.00194969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A40FBD8-2D6F-46C0-945A-316A04A909FA</gtr:id><gtr:title>Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cb31d2e26049f6f3b6d71f441fa4fc1"><gtr:id>8cb31d2e26049f6f3b6d71f441fa4fc1</gtr:id><gtr:otherNames>Makarona K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5461f44244baa7.64218142</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9086C1B-3E49-4B3E-A56D-9FD92523A83E</gtr:id><gtr:title>Down syndrome preleukemia and leukemia.</gtr:title><gtr:parentPublicationTitle>Pediatric clinics of North America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/934a6409bc7751c746c8ab3ea4f3924b"><gtr:id>934a6409bc7751c746c8ab3ea4f3924b</gtr:id><gtr:otherNames>Maloney KW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-3955</gtr:issn><gtr:outcomeId>58c3e3b35b0ec7.44739456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9546D50-48D4-4D8E-B295-4374A2FEA97B</gtr:id><gtr:title>Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a153ccf6d3e6dd4a10a5fe993d848d64"><gtr:id>a153ccf6d3e6dd4a10a5fe993d848d64</gtr:id><gtr:otherNames>Psaila B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>58c3e29f196d93.20492056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E79C8F28-FFD1-48E7-8A25-20FB5949ADCC</gtr:id><gtr:title>MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0686fc6871b4d66bec677c0c31347ecd"><gtr:id>0686fc6871b4d66bec677c0c31347ecd</gtr:id><gtr:otherNames>Kerry J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58c3e04a9e86c3.38988692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC07398E-8AAD-47EC-A5D9-43AFBE99FB68</gtr:id><gtr:title>High resolution IgH repertoire analysis reveals fetal liver as the likely origin of life-long, innate B lymphopoiesis in humans.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4f5d0920d73a0a7caca3b42bf26d5a4"><gtr:id>f4f5d0920d73a0a7caca3b42bf26d5a4</gtr:id><gtr:otherNames>Roy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>5aa6b0a0ec06b3.88574489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFCD6C4B-45FA-43E2-BF51-6FBCB124169E</gtr:id><gtr:title>Stem and progenitor cell dysfunction in human trisomies.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4377ed4861af442d6d8939bfb897ce6"><gtr:id>a4377ed4861af442d6d8939bfb897ce6</gtr:id><gtr:otherNames>Liu B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>567a83f6d21302.57315906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42CB4C3B-616A-4207-8407-B691A306CAE0</gtr:id><gtr:title>Prenatal therapy in transient abnormal myelopoiesis: a systematic review.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood. Fetal and neonatal edition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73ab14008cb33c7de3145123dad84a70"><gtr:id>73ab14008cb33c7de3145123dad84a70</gtr:id><gtr:otherNames>Tamblyn JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-2998</gtr:issn><gtr:outcomeId>567a83c5860568.88699371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64897100-DE14-4A12-842B-43F2E95546BF</gtr:id><gtr:title>Ribonuclease inhibitor 1 regulates erythropoiesis by controlling GATA1 mRNA translation.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f01461a4b8d1c670adeeb1dcf0f18c5"><gtr:id>5f01461a4b8d1c670adeeb1dcf0f18c5</gtr:id><gtr:otherNames>Chennupati V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>5aa6b0356b4392.44830205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12B2F1B1-01F5-442F-8587-40F067B48F66</gtr:id><gtr:title>Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiency.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad132f288ab3a9e158b8d87fb3db484c"><gtr:id>ad132f288ab3a9e158b8d87fb3db484c</gtr:id><gtr:otherNames>Costa JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5461f4428cc7f9.56093525</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12009/14</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>